The mammalian FGF family comprises 18 structurally-related polypeptides, which have traditionally been known as paracrine acting mitogens and morphogens that mediate key processes throughout embryonic development. The discovery that three members of this family act as hormones has transformed the FGF signaling field and sparked major drug discovery activities centered on these ligands in both academia and pharmaceutical industries. FGF21 has been studied as an anti-diabetic drug candidate owing to its glucose- and lipid-lowering action, and various FGF21 agonists are already being tested in clinical trials for use in type II diabetes, obesity, and related metabolic disorders. Antagonists to FGF23, a key regulator of phosphate homeostasis, are being developed as the first causative therapy for patients with renal phosphate wasting disorders to block the action of excess FGF23 in these patients, and are also considered for treating cardiovascular disease in chronic kidney disease. FGFs carry out their diverse functions by binding, dimerizing, and thereby activating the FGF receptor (FGFR) subfamily of RTKs. The classic paracrine FGF ligands require heparin sulfate (HS) as a cofactor for activating FGFRs, whereas the hormone-like FGFs depend on Klotho coreceptors. HS- or Klotho-assisted FGF-FGFR dimerization enables the trans- phosphorylation on cytoplasmic kinase A-loop tyrosines to activate the autoinhibited ?catalytically-repressed? FGFR kinases, and therefore is a mandatory step in FGF signal transduction. The tremendous biomedical significance of FGF signaling has been the driving force behind the studies on the structural basis of this signaling system, which my laboratory has been spearheading since inception of this grant in 2000. Building upon the achievements of the previous grant cycles, in this competing renewal we propose three Specific Aims to address imminent knowledge gaps in FGF signaling that will have a significant and persistent impact on FGF/RTK signaling and its therapeutic targeting.
Aims I & II will unravel the mechanisms by which Klotho coreceptors assist endocrine FGFs to dimerize and activate their cognate FGFRs, and hence pave the way for the discovery of novel therapeutics for major metabolic diseases, such as type II diabetes, obesity, and chronic kidney disease, which pose some of the biggest threats to public health and worldwide economy.
Aim III will exploit a unique gain-of-function mutation in FGFR to solve the longstanding paradox of how unphosphorylated catalytically-repressed RTKs perform the initial A-loop tyrosine transphosphorylation to become activated. Our discovery of an unprecedented ?induced fit? asymmetric dimerization of FGFR kinases, which triggers A-loop tyrosine phosphorylation by overcoming an autoinhibitory charge repulsion, will advance our comprehension of signal transduction by majority of RTKs that rely on A-loop tyrosine transphosphorylation as the activating step.
This Aim will also provide the details of how this pathogenic mutation hijacks the physiological mechanism underlying A-loop tyrosine phosphorylation to confer gain-of-function on the kinase.
The objectives of this application are: 1) to elucidate the molecular mechanisms by which the recently discovered hormone-like FGFs activate their cognate FGF receptors (FGFRs) to regulate glucose/lipid and phosphate/vitamin D homeostasis in humans, and 2) to understand how pathogenic mutations hijack the physiological mechanism of FGFR activation to cause severe forms of human skeletal disorders. In addition to advancing our understanding of FGF signaling in human development, metabolism, and disease, the findings of the proposed studies are expected to open up new windows of opportunity for developing drugs for some of the most prominent human diseases, such as type II diabetes, obesity, and chronic kidney disease, which impose an enormous medical, social, and economic burden worldwide.
|Agoro, Rafiou; Montagna, Anna; Goetz, Regina et al. (2018) Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J 32:3752-3764|
|Liang, Guang; Song, Lintao; Chen, Zilu et al. (2018) Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int 93:95-109|
|Chen, Gaozhi; Liu, Yang; Goetz, Regina et al. (2018) ?-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553:461-466|
|Liu, Yang; Ma, Jinghong; Beenken, Andrew et al. (2017) Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. Structure 25:1325-1336.e3|
|Huang, Chahua; Liu, Yang; Beenken, Andrew et al. (2017) A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration. Cardiovasc Res 113:1585-1602|
|Xu, C; Lang-Muritano, M; Phan-Hug, F et al. (2017) Genetic testing facilitates prepubertal diagnosis of congenital hypogonadotropic hypogonadism. Clin Genet 92:213-216|
|Somm, Emmanuel; Henry, Hugues; Bruce, Stephen J et al. (2017) ?-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight 2:|
|Huang, Zhifeng; Tan, Yi; Gu, Junlian et al. (2017) Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell Rep 20:1717-1728|
|Johnson, Kristen; Levine, Kymberly; Sergi, Joseph et al. (2017) Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. J Bone Miner Res 32:2062-2073|
|Xu, Cheng; Messina, Andrea; Somm, Emmanuel et al. (2017) KLB, encoding ?-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. EMBO Mol Med 9:1379-1397|
Showing the most recent 10 out of 91 publications